View in Other Languages Relatório do Mercado Australiano de 24 de Fevereiro de 2011: A Viralytics (ASX:VLA) Recebeu Aviso da Decisão Chinesa de Outorga de Patente de Uso para o EVATAK(TM) em Câncer de ovário Reporte del Mercado Australiano, 24 de febrero de 2011: China otorga a Viralytics (ASX:VLA) Patente por el uso de EVATAK(TM) para Cáncer de Ovario Laporan Pasar Australia 24 Februari 2011: Viralytics (ASX:VLA) Menerima Pemberitahuan dari Cina atas Kebijakan Pemberian Paten untuk Penggunaan EVATAK (TM) bagi Kanker Ovarian Rapport du marché australien en date du 24 février 2011: Viralytics (ASX:VLA) reçoit un avis de décision de la Chine d’accorder une patente pour l’utilisation de l’EVATAK(TM) dans le traitement du cancer de l’ovaire تقرير السوق الاسترالية 24 شباط/فبراير، 2011: تلقت شركة Viralytics ASX:VLA إشعار بقرار السلطات الصينية منح إجازة إستخدام عقار EVATAK TM لعلاج سرطان المبيض. รายงานการตลาดออสเตรเลีย วันที่ 24 กุมภาพันธ์ ค.ศ. 2011:ไวรัลลิติกส์ (Viralytics) (ASX:VLA) ได้รับหนังสือจากประเทศจีน แจ้งการอนุมัติให้ใช้สิทธิบัตร EVATAK(TM) เพื่อรักษามะเร็งรังไข่ 2011年2月24日澳洲股市:Viralytics (ASX:VLA)收到中国颁发的有关使用EVATAK(TM)治疗卵巢癌的专利批准通知 Australischer Marktbericht, 24. Februar 2011: Viralytics (ASX:VLA) erhält Patent-Genehmigung aus China für die Anwendung von EVATAK(TM) gegen Eierstockkrebs 2011년 2월24일 호주 시장보고서: Viralytics (ASX:VLA), 중국에서 난소암 치료제 EVATAK(TM) 특허 확보 2011年2月24日澳洲股市:Viralytics (ASX:VLA)收到中國頒發的有關使用EVATAK(TM)治療卵巢癌的專利批准通知 オーストラリア市場レポート 2011年2月24日: Viralytics (ASX:VLA) は卵巣がんへの EVATAK(TM) 使用に関し中国から特許付与決定通知を取得 Australian Market Report of February 24, 2011: Viralytics (ASX:VLA) Receive Chinese Notice To Grant Patent Of Use Of EVATAK(TM) In Ovarian Cancer 
Australian Market Report of February 24, 2011: Viralytics (ASX:VLA) Receive Chinese Notice To Grant Patent Of Use Of EVATAK(TM) In Ovarian Cancer
Australian Market Report of February 24, 2011: Viralytics (ASX:VLA) Receive Chinese Notice To Grant Patent Of Use Of EVATAK(TM) In Ovarian Cancer

Sydney, Feb 24, 2011 AEST (ABN Newswire) - Viralytics Limited (googlechartASX:VLA) received a patent granting notice from China regarding the use of EVATAK(TM) as an anti-cancer agent in human ovarian cancer. The Company also has a Phase II Investigational New Drug application for late stage melanoma patients under discussion with the US Food and Drug Administration using its lead oncolytic virus, CAVATAK(TM). Two Phase I safety trials in Australia, studying the safety of both intratumoural and intravenous delivery of CAVATAK(TM) are currently underway.

Peak Resources Limited (googlechartASX:PEK) reported the remaining assay results from the November-December 2010 RC and diamond drilling campaign in the central hills area at Ngualla. The Southern Rare Earth Zone has been further extended reporting results including 8m at 5.18% REO, 30.69m at 4.51% REO and 19m at 4.98% REO. Assay results from the northern niobium-tantalum zone have returned the highest grades of niobium, tantalum and phosphate encountered to date.

Ferrum Crescent Limited (googlechartASX:FCR) has commenced a programme of reverse circulation and diamond core drilling at the Moonlight Iron Ore Project in South Africa. The drilling will provide additional geological understanding in important areas of the deposit and provide bulk sample for the first stage of an ongoing metallurgical testwork programme. Moonlight contains a JORC compliant resource of 74Mt in the Indicated Resource category and 225Mt in the Inferred Resource category. The Company anticipates an upgraded resource statement in Q2 2011.

United Uranium Limited (googlechartASX:UUL) is pleased to announce that the No.1 Institute of Geology and Minerals of Shandong Province ("SDGM") has received formal approval from the Foreign Investment Review Board (FIRB) to subscribe for 5,600,000 shares in the Company at an issue price of 21 cents per share for total consideration of A$1,176,000. FIRB has also provided formal approval for SDGM to acquire up to 51% of the issued capital of the Company and up to a 50% interest in six tenements. United Uranium will work with SDGM to further advance these tenements in the Northern Territory.

Gindalbie Metals Limited (googlechartASX:GBG) announced today that the maiden shipment of iron ore from the Karara Iron Ore Project in Western Australia will occur within two months, following the signing of a hematite ore sales agreement with Sinosteel Midwest Corporation. The agreement, for a total of 480,000 tonnes of high-grade direct shipping ore mined at Karara, marks the effective transition of the Project to production well ahead of the completion of project construction later this year.

Contact

Asia Business News
Tel: +61-2-9247-4344
http://www.abnnewswire.net


ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 21) (Last 30 Days: 99) (Since Published: 13898) 

View in Other Languages 331873211629919280522791026157192341666015882154951430913898 (272819)

googlechart